Vertex names Jonathan Poole CFO effective Jan 1, 2027; Wagner stays COO

VERTEX PHARMACEUTICALS INC / MA

Jonathan Poole, 51, appointed EVP & CFO effective Jan 1, 2027; was SVP Finance since March 2020.
Charles Wagner ceases as CFO on that date but remains EVP & COO.
Poole receives $750,000 base salary and 90% target bonus; severance equals 100% of base plus target bonus.
Change-of-control agreement provides 100% base/target bonus, pro-rated bonus, and full equity vesting on qualifying termination.
Poole previously CFO at Evelo Biosciences (2018-2020) and Genocea Biosciences (2014-2018).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.